P/E ratio for NeoGenomics (NEO)
P/E ratio as of April 2024 (TTM): -14.9
According to NeoGenomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.9457. At the end of 2022 the company had a P/E ratio of -7.97.
P/E ratio history for NeoGenomics from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.97 | -98.6% |
| 2021 | -569 | -131.69% |
| 2020 | > 1000 | 329.49% |
| 2019 | 418 | 111.36% |
| 2018 | 198 | -412.39% |
| 2017 | -63.3 | 188% |
| 2016 | -22.0 | -87.44% |
| 2015 | -175 | -192.61% |
| 2014 | 189 | 161.31% |
| 2013 | 72.3 | -107.34% |
| 2012 | -985 | 2011.36% |
| 2011 | -46.7 | 223.08% |
| 2010 | -14.4 | -42.22% |
| 2009 | -25.0 | 104.92% |
| 2008 | -12.2 | 24.26% |
| 2007 | -9.82 | -100.36% |
| 2006 | > 1000 | -58149.54% |
| 2005 | -4.75 | -24% |
| 2004 | -6.25 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Quest Diagnostics
DGX | 19.0 | -227.32% | 🇺🇸 USA |
 LabCorp LH | 27.0 | -280.90% | 🇺🇸 USA |
 RadNet RDNT | -208 | 1,290.83% | 🇺🇸 USA |
 Psychemedics PMD | -7.77 | -48.02% | 🇺🇸 USA |
 Enzo Biochem ENZ | -1.23 | -91.74% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.